TCMP
NVO

Thrive Capital Management (Pennsylvania)’s Novo Nordisk NVO Stock Holding History

Thrive Capital Management (Pennsylvania)’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,595
Closed -$228K – 185
2024
Q2 		$228K Buy
+1,595
New +$211K 0.1% 169
2024
Q1 		– Sell
-4,223
Closed -$437K – 181
2023
Q4 		$437K Buy
4,223
+544
+15% +$53.8K 0.23% 72
2023
Q3 		$335K Buy
3,679
+409
+13% +$36K 0.19% 86
2023
Q2 		$265K Buy
+3,270
New +$267K 0.15% 104

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Thrive Capital Management (Pennsylvania)'s NVO Position: Q3 2024 in Review

Thrive Capital Management (Pennsylvania) sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 1,595 shares — an estimated $228K sold.

Thrive Capital Management (Pennsylvania) first reported a position in NVO in Q2 2023 and held it in 4 quarters. The position peaked at $437K in Q4 2023. 1,784 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • Thrive Capital Management (Pennsylvania) reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
  • Thrive Capital Management (Pennsylvania) sold 1,595 Novo Nordisk shares in Q3 2024, an estimated $228K.
  • Thrive Capital Management (Pennsylvania) first reported a position in Novo Nordisk in Q2 2023 and held it in 4 quarters.
  • Thrive Capital Management (Pennsylvania)'s Novo Nordisk position peaked at $437K in Q4 2023.
  • 1,784 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q3 2024, filed 13 Nov 2024.